l.diallo

TL2 · Plovdiv

Contributes reviews on supplier material. Based in Plovdiv.

Joined 21 October 2024 · last posted 4d

63 posts, newest first. Showing up to 150.

PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #23 · Compounds › Oral incretins · 24 Jul 2026 · 5 likes Thank you — that answers what I came here to find out.
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #94 · Evidence › Journal club · 21 Jul 2026 · 7 likes What I would want before treating SUSTAIN 6 as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually…
Pages past their review date, listed — does this still hold? Replied, post #53 · Meta › Wiki maintenance · 15 Jul 2026 · 0 likes Housekeeping: three documents now carry the same paragraph verbatim because it was copied rather than linked. One of them should hold it and the other two should point…
Why 99.2% and 97.8% on the same lot can both be correct Replied, post #17 · Analytics › HPLC & UHPLC · 12 Jul 2026 · 0 likes Thank you for the correction. I would rather find out here than later.
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #66 · Analytics › Home & field testing · 8 Jul 2026 · 6 likes Ultraviolet absorbance at 280 nanometres estimates concentration for peptides containing aromatic residues and gives nothing for peptides that do not. Knowing which…
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #24 · Compounds › Semaglutide · 26 Jun 2026 · 7 likes On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species.…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #99 · Outcomes › Body composition · 20 Jun 2026 · 0 likes Worth separating two things that post #95 runs together. Where I would push back on the Lean mass preservation consensus is the confidence, not the direction. The…
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #30 · Sourcing › Independent verification · 20 Jun 2026 · 14 likes What a supplier does when asked is itself information, and it is information that a chromatogram cannot provide. The uncertainty is in the assumption, not in the…
About the Mass spectrometry category Replied, post #3 · Analytics › Mass spectrometry · 13 Jun 2026 · 23 likes As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic…
Revisiting: The arithmetic of an intermediate dose between two label steps Replied, post #46 · Practice › Dosing & titration · 22 May 2026 · 21 likes Taking post #43 at face value and following it one step further. The starting dose in most of these programmes is a tolerance step and produces little effect by design.…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #25 · Compounds › Repair & healing peptides · 14 May 2026 · 33 likes The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic…
Request: show the solution author in the topic list — what changed since Replied, post #88 · Meta › Feature requests · 4 May 2026 · 5 likes Alternatives: if you have thought of a way the current site might already serve your need, mention it. It helps assess whether the feature is truly missing or just not…
Spike-and-recover accuracy for a peptide assay Replied, post #23 · Analytics › Method validation · 7 Apr 2026 · 3 likes Useful. I had the fact and not the reason, which turns out to be the important half.
Prescription portability between countries Replied, post #3 · Access › International · 6 Apr 2026 · 13 likes Clear enough that I do not think I have a follow-up, which is unusual.
Bug report: the reconstitution calculator and a rounding edge case Replied, post #7 · Data & Tools › Calculators · 1 Apr 2026 · 15 likes Rounding behaviour is where two tools disagree. One rounding to the nearest graduation and one to two decimal places will produce different advice from identical inputs.
Reading a syringe in poor light, and how to avoid needing to — what changed since Replied, post #3 · Devices › Syringes & needles · 21 Mar 2026 · 3 likes Bookmarking this. I will come back when I have something worth adding.
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #29 · Lounge › Introductions · 10 Mar 2026 · 5 likes If you are arriving from somewhere louder, the pace here will feel slow. A topic can sit for two days and then get a reply that is worth the wait. That is the design…
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #4 · Evidence › Trials · 8 Mar 2026 · 2 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #90 · Access › Pricing · 15 Feb 2026 · 0 likes Where a price includes consultation, device and follow-up, saying so makes a comparison possible. Most quoted figures do not. Reading it again, the caveat matters more…
A plateau that disappeared when I changed how I measured Replied, post #12 · Outcomes › Progress reports · 31 Jan 2026 · 2 likes Seconded. It reads as careful rather than confident, which is the right register.
Recording a dissent on a document rather than suppressing it Replied, post #2 · Documentation › Doc review · 16 Jan 2026 · 7 likes Approving a document you have not read is worse than not responding, and it happens because approval feels supportive.
Research-use-only labelling: what it means and what it does not Replied, post #84 · Sourcing › Regulatory · 7 Jan 2026 · 17 likes Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling…
Follow-up: Evidence quality in the secretagogue literature: an honest assessment Replied, post #6 · Compounds › Secretagogues & GH axis · 2 Jan 2026 · 0 likes I would rather this thread reach "we do not know" about Evidence quality than reach a confident answer that nobody can support when asked.
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #34 · Sourcing › Red flags · 1 Jan 2026 · 0 likes Unresponsiveness: a supplier that does not reply to reasonable requests for documentation or clarification is showing you something about how they operate.
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #42 · Access › Pricing · 21 Dec 2025 · 3 likes Price changes has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Guidelines revision: what changed and why — one year on Replied, post #45 · Meta › Announcements · 11 Dec 2025 · 10 likes Thank you for announcing it in advance rather than after. The number of places that do the reverse is remarkable.
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #65 · Compounds › Semaglutide · 9 Dec 2025 · 21 likes The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is…
[2026 update] How much of the diluent volume the powder itself displaces Replied, post #74 · Practice › Reconstitution · 26 Nov 2025 · 18 likes Add the diluent down the side of the vial rather than directly onto the cake. It is slower and it avoids the foaming that makes people think something has gone wrong.
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #53 · Compounds › Other compounds · 24 Nov 2025 · 5 likes An observation about Sequence verification that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than…
[2026 update] Are there stupid questions here? A staff answer, at length Replied, post #8 · marked as the solution · Start Here › Welcome · 12 Nov 2025 · 6 likes Nothing here requires expertise. The experienced members here got that way by posting questions, not by knowing the answer before they showed up. If you know something…
How to read a phase 2 result without treating it as a phase 3 result — what changed since Replied, post #15 · Compounds › Retatrutide · 10 Nov 2025 · 0 likes On post #11 — agreed on the reasoning, with one qualification. Discontinuation for adverse effects in phase 2 was not negligible at the higher doses. That figure…
Second pass at: How to ask a question when you cannot say why you are asking it Replied, post #29 · Start Here › How to Ask · 4 Nov 2025 · 0 likes Units. Everything needs units. This is why we ask every single time. I have seen the same arithmetic done three different ways depending on whether the person was…
Which panel is worth repeating and which is worth ignoring Replied, post #134 · Clinical › Bloodwork · 10 Oct 2025 · 11 likes Following this. I have the same question and no better information than the first post.
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Replied, post #30 · Clinical › Special populations · 3 Oct 2025 · 8 likes Post-surgical populations, particularly after procedures affecting the gastrointestinal tract, interact with a delayed-emptying mechanism in ways that need specialist…
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #39 · Compounds › Oral incretins · 17 Sep 2025 · 0 likes Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation…
Documenting an adverse event properly Replied, post #5 · Safety › Adverse events · 12 Sep 2025 · 31 likes Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance…
Reading SURMOUNT-1 without the press release — one year on Replied, post #7 · Compounds › Tirzepatide · 9 Sep 2025 · 0 likes Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you…
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #34 · Evidence › Journal club · 20 Aug 2025 · 0 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend. Happy to expand any of that if it is the useful part.
Follow-up: The decimal-point error, and the habit that catches it Replied, post #4 · Practice › Reconstitution · 25 May 2025 · 5 likes The opening post describes the usual case. This is about the unusual one. Agreed on decimal-point error, with one qualification that I think matters. The reasoning…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #126 · Sourcing › Independent verification · 20 May 2025 · 28 likes Answering the question post #124 raises rather than the one it answers. Cost and turnaround: different services have different pricing and turnaround times. Janoshik's…
A claim built entirely on a subgroup analysis Replied, post #31 · Evidence › Study critique · 12 May 2025 · 25 likes Post #28 is right about the mechanism and I think understates the practical bit. The most useful reply I ever got about claim built was a request to state my units. It…
Scheduled maintenance and what will be unavailable Replied, post #126 · Meta › Announcements · 28 Apr 2025 · 0 likes Worth separating two things that post #125 runs together. My understanding of scheduled maintenance is a few years old and may have been superseded. If it has been, I…
Follow-up: What other technical communities get right that we do not Replied, post #56 · Lounge › Off topic · 2 Apr 2025 · 0 likes Lower-stakes conversation that does not belong in the technical categories. Still civil, still sourced when a claim is made, but the bar for relevance is lower. Take it…
Ipamorelin selectivity claims and where they came from Replied, post #21 · Compounds › Secretagogues & GH axis · 18 Mar 2025 · 0 likes Answering the question post #19 raises rather than the one it answers. Second-hand on ipamorelin selectivity claims, so weight it accordingly — someone whose method I…
Maintainer handover: how it works Replied, post #40 · Meta › Wiki maintenance · 16 Mar 2025 · 29 likes Taking post #37 at face value and following it one step further. Careful with that. A short duplicated paragraph is sometimes better than a link, because the reader who…
When to suspect the method rather than the sample Replied, post #81 · Analytics › Method validation · 13 Feb 2025 · 0 likes Reporting a result to more decimal places than the method's precision supports is a small dishonesty that appears everywhere. A method with a two per cent relative…
Consistent declarations and why they matter more than clever ones Replied, post #13 · Sourcing › Logistics · 9 Feb 2025 · 0 likes Post #12 is right about the mechanism and I think understates the practical bit. One more thing on consistent declarations that took me far too long to see: the two…
Revisiting: What a well-designed human trial of a secretagogue would look like Replied, post #50 · Compounds › Secretagogues & GH axis · 25 Jan 2025 · 32 likes The most useful single question to ask about any compound in this family is what the published human evidence actually consists of. In several cases the honest answer…
A supplier that answers analytical questions with restated claims Replied, post #9 · Sourcing › Red flags · 12 Jan 2025 · 12 likes Nothing here should be read as an accusation against a named company, and the guidelines exist so that reports remain reports. I keep a log of this specifically because…
Follow-up: Individual participant data versus aggregate data Replied, post #92 · Evidence › Meta-analyses · 11 Jan 2025 · 3 likes Sensitivity analysis: the authors re-run the meta-analysis excluding studies one at a time, or by quality, to see whether the pooled estimate changes. Robust results…
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #51 · Compounds › Semaglutide · 28 Dec 2024 · 1 like Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely…
Here for the analytics and not much else — one year on Replied, post #10 · Lounge › Introductions · 25 Dec 2024 · 13 likes Welcome. If you have an analytical background you will find the analytics subcategories the easiest place to be useful quickly — the recurring gap here is people who…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #13 · Compounds › Semaglutide · 18 Dec 2024 · 4 likes Useful. I have added it to my own notes with the date on it.
Body image changing more slowly than the body Replied, post #50 · Wellbeing › Mental health · 16 Dec 2024 · 28 likes Social and relationship impacts: weight change affects how others perceive and interact with a person. Those impacts are real and can be psychologically significant.
Time to steady state after a dose increase Replied, post #12 · Pharmacology › Pharmacokinetics · 2 Nov 2024 · 6 likes Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments…
[2026 update] Step therapy requirements and how to satisfy them Replied, post #6 · Access › Insurance & coverage · 27 Oct 2024 · 8 likes Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
Promotion criteria, and the one that stops most nominations Replied, post #82 · Documentation › Doc review · 10 Oct 2024 · 30 likes Adding a note of thanks rather than an opinion. I did not know most of that.
Follow-up: A site rotation scheme that is easy enough to actually follow Replied, post #69 · Practice › Administration · 1 Oct 2024 · 3 likes Answering the question post #65 raises rather than the one it answers. A site rotation scheme that actually works: abdomen, outer thigh, back of arm, outer hip. Rotate…
Second pass at: Food noise reducing and the disorientation that can follow Replied, post #4 · Wellbeing › Mental health · 24 Sep 2024 · 0 likes Narrowing post #3, because the general version has more than one answer. Where the Food noise discussion usually stalls is that nobody wants to say "I do not know" and…
Blind submission and why it changes minds Replied, post #24 · Sourcing › Independent verification · 28 Jul 2024 · 32 likes The arithmetic in post #23 is right; the assumption feeding it is the part to check. Repeat testing: if you want to verify the same lot a second time, testing with a…
Guidelines revision: what changed and why Replied, post #62 · Meta › Announcements · 26 Jul 2024 · 2 likes Adding a null result on guidelines revision. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #67 · Practice › Dosing & titration · 8 Jul 2024 · 17 likes The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat…
The mass-error checker and its intended scope Replied, post #45 · Data & Tools › Calculators · 12 Jun 2024 · 0 likes Tools that run entirely in the browser send nothing anywhere, which matters more to some people here than others and is worth stating either way. Filing this under…